gemcitabine has been researched along with veliparib in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (66.67) | 24.3611 |
| 2020's | 4 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Flatten, KS; Huehls, AM; Huntoon, CJ; Karnitz, LM; Kaufmann, SH; Sutor, SL; Wahner Hendrickson, AE | 1 |
| Ai, Y; Brody, JR; Burkhart, RA; Cozzitorto, JA; Gehrmann, M; Lal, S; Liang, Q; Miller, K; Napper, A; Norris, ZA; Peng, Y; Sawicki, JA; Talbott, VA; Tholey, RM; Winter, JM; Witkiewicz, AK; Yeo, CJ; Zhuang, Z | 1 |
| Matsumoto, K; Onda, T; Yaegashi, N | 1 |
| Almokadem, S; Appleman, L; Belani, CP; Beumer, JH; Carneiro, BA; Chen, A; Chu, E; Ding, F; Hershberger, PA; Holleran, J; Jiang, Y; Ken Czambel, R; Kiesel, BF; Kontopodis, E; Lin, Y; Petro, D; Puhalla, S; Rachid, M; Schmitz, JC; Stoller, R | 1 |
| Brenner, R; Capanu, M; Chen, AP; Dhani, N; Do, RK; Epstein, AS; Estrella, H; Golan, T; Kelsen, DP; Kindler, HL; Lee, JW; Lowery, MA; Maynard, H; Moore, MJ; O'Reilly, EM; Salo-Mullen, EE; Segal, A; Segal, M; Stadler, ZK; Tang, LH; Yu, KH | 1 |
| Bell-McGuinn, K; Cristea, M; Fleming, GF; Gray, HJ; Luo, Y; Martin, LP; McKee, MD; Munasinghe, W; Sullivan, D; Xiong, H | 1 |
| Bryant, M; Davis, MJ; Hendifar, A; Hoffman, D; Jamil, L; Kim, S; Klempner, SJ; Lo, S; Nissen, N; Noe, P; Osipov, A; Piantadosi, S; Placencio-Hickok, V; Ristow, L; Rokhsar, S; Sandler, H; Scher, K; Shiao, SL; Tighiouart, M; Tuli, R; Wachsman, A | 1 |
| Fazio, N | 1 |
| Kelsen, DP; O'Reilly, EM; Park, W | 1 |
| Chovanec, M; Kalavska, K; Mardiak, J; Mego, M; Obertova, J; Palacka, P; Reckova, M; Rejlekova, K; Svetlovska, D; Sycova-Mila, Z | 1 |
1 review(s) available for gemcitabine and veliparib
| Article | Year |
|---|---|
Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Doxorubicin; Everolimus; Female; Folic Acid; Gemcitabine; Humans; Indazoles; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Nivolumab; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Glycols; Pyrimidines; Quinazolines; Recombinant Fusion Proteins; Sirolimus; Sulfonamides; Topotecan; TOR Serine-Threonine Kinases; Vinca Alkaloids | 2015 |
5 trial(s) available for gemcitabine and veliparib
| Article | Year |
|---|---|
Phase I study of veliparib in combination with gemcitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Deoxycytidine; Female; Gemcitabine; Humans; Male; Neoplasms | 2017 |
Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; Carcinoma, Pancreatic Ductal; Cisplatin; Cohort Studies; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Germ-Line Mutation; Heterozygote; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Survival Rate | 2018 |
Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bayes Theorem; Benzimidazoles; Bile Duct Neoplasms; Breast Neoplasms; Carboplatin; Carcinoma, Basal Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Genes, BRCA1; Genes, BRCA2; Germ-Line Mutation; Humans; Induction Chemotherapy; Kidney Neoplasms; Kidney Pelvis; Liver Neoplasms; Lung Neoplasms; Maintenance Chemotherapy; Male; Maximum Tolerated Dose; Mesothelioma; Middle Aged; Nausea; Neoplasm Metastasis; Neutropenia; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Prostatic Neoplasms; Skin Neoplasms; Thrombocytopenia; Treatment Outcome | 2018 |
A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Microsatellite Instability; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Prognosis; Radiotherapy; Treatment Outcome | 2019 |
Gemcitabine, carboplatin and veliparib in multiple relapsed/refractory germ cell tumours: The GCT-SK-004 phase II trial.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasms, Germ Cell and Embryonal; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Young Adult | 2021 |
6 other study(ies) available for gemcitabine and veliparib
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status.
Topics: Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; cdc25 Phosphatases; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 1; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Immunoblotting; Ovarian Neoplasms; Phosphorylation; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Protein Kinases; Protein Serine-Threonine Kinases; Pyrazines; Pyrazoles; Pyrimidines; RNA Interference; Signal Transduction; Sulfones; Topotecan | 2013 |
Mitoxantrone targets human ubiquitin-specific peptidase 11 (USP11) and is a potent inhibitor of pancreatic cancer cell survival.
Topics: Antineoplastic Agents; Benzimidazoles; BRCA2 Protein; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; DNA Damage; Drug Screening Assays, Antitumor; Gemcitabine; Gene Silencing; High-Throughput Screening Assays; Humans; Mitoxantrone; Pancreatic Neoplasms; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Thiolester Hydrolases | 2013 |
Cisplatin Plus Gemcitabine as Standard of Care for Germline
Topics: Adenocarcinoma; Benzimidazoles; Cisplatin; Deoxycytidine; Fanconi Anemia Complementation Group N Protein; Gemcitabine; Germ Cells; Humans; Mutation; Pancreas; Pancreatic Neoplasms; Standard of Care | 2020 |
Reply to N. Fazio.
Topics: Adenocarcinoma; Benzimidazoles; Cisplatin; Deoxycytidine; Fanconi Anemia Complementation Group N Protein; Gemcitabine; Germ Cells; Humans; Mutation; Pancreas | 2020 |